EUVIMEDEUVIMED entdecken
Open Access

Impact of Diabetes and Glycemia on Cardiac Improvement and Adverse Events Following Mechanical Circulatory Support

Christos P Kyriakopoulos iD, Iosif Taleb iD, Eleni Tseliou iD, Konstantinos Sideris iD, Rana Hamouche iD, Eleni Maneta iD, Marisca Nelson, Ethan Krauspe iD, Sean Selko iD, Joseph R Visker iD, Elizabeth Dranow iD, Matthew L Goodwin iD und 7 weitere

Journal of the American Heart Association · 2024

DOI: 10.1161/jaha.123.032936 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, 2024. Verfasst von Christos P Kyriakopoulos und 18 weiteren Autor:innen. Beteiligte Einrichtung: Utah Cardiac Recovery (UCAR) Program (University of Utah Health & School of Medicine, Intermountain Medical Center, and George E. Wahlen Department o…. Hauptthemen laut MEDLINE: Heart-Assist Devices, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Heart Failure. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NHLBI NIH HHS, CSRD VA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background Type 2 diabetes is prevalent in cardiovascular disease and contributes to excess morbidity and mortality. We sought to investigate the effect of glycemia on functional cardiac improvement, morbidity, and mortality in durable left ventricular assist device (LVAD) recipients. Methods and Results Consecutive patients with an LVAD were prospectively evaluated (n=531). After excluding patients missing pre‐LVAD glycated hemoglobin (HbA1c) measurements or having inadequate post‐LVAD follow‐up, 375 patients were studied. To assess functional cardiac improvement, we used absolute left ventricular ejection fraction change (ΔLVEF: LVEF post‐LVAD−LVEF pre‐LVAD). We quantified the association of pre‐LVAD HbA1c with ΔLVEF as the primary outcome, and all‐cause mortality and LVAD‐related adverse event rates (ischemic stroke/transient ischemic attack, intracerebral hemorrhage, gastrointestinal bleeding, LVAD‐related infection, device thrombosis) as secondary outcomes. Last, we assessed HbA1c differences pre‐ and post‐LVAD. Patients with type 2 diabetes were older, more likely men suffering ischemic cardiomyopathy, and had longer heart failure duration. Pre‐LVAD HbA1c was inversely associated with ΔLVEF in patients with nonischemic cardiomyopathy but not in those with ischemic cardiomyopathy, after adjusting for age, sex, heart failure duration, and left ventricular end‐diastolic diameter. Pre‐LVAD HbA1c was not associated with all‐cause mortality, but higher pre‐LVAD HbA1c was shown to increase the risk of intracerebral hemorrhage, LVAD‐related infection, and device thrombosis by 3 years on LVAD support ( P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart-Assist DevicesDiabetes Mellitus, Type 2Glycated HemoglobinHeart FailureVentricular Function, LeftBlood GlucoseHumansMaleFemaleMiddle AgedAgedProspective StudiesStroke VolumeTreatment OutcomeRecovery of FunctionRisk FactorsTime Factors

Stichwörter der Autor:innen

diabetesheart assist deviceheart failureleft ventricular assist devicemyocardial recoveryreverse remodeling

Substanzen

Glycated HemoglobinBlood Glucosehemoglobin A1c protein, human

Autor:innen und Institutionen

  • Utah Cardiac Recovery (UCAR) Program (University of Utah Health & School of Medicine, Intermountain Medical Center, and George E. Wahlen Department of Veterans Affairs Medical Center) Salt Lake City UT USA.
  • Nora Eccles Harrison Cardiovascular Research and Training Institute, University of Utah Salt Lake City UT USA.

ORCID-Profile: Christos P Kyriakopoulos, Iosif Taleb, Eleni Tseliou, Konstantinos Sideris, Rana Hamouche, Eleni Maneta, Ethan Krauspe, Sean Selko, Joseph R Visker, Elizabeth Dranow, Matthew L Goodwin, Rami Alharethi, Omar Wever-Pinzon, James C Fang, Josef Stehlik, Craig H Selzman, Thomas C Hanff, Stavros G Drakos

Förderung

  • NCATS NIH HHS
  • NHLBI NIH HHS
  • CSRD VA

Zitieren

APA

Kyriakopoulos, C. P., Taleb, I., Tseliou, E., Sideris, K., Hamouche, R., Maneta, E., Nelson, M., Krauspe, E., Selko, S., Visker, J. R., Dranow, E., Goodwin, M. L., Alharethi, R., Wever-Pinzon, O., Fang, J. C., Stehlik, J., Selzman, C. H., Hanff, T. C., & Drakos, S. G. (2024). Impact of Diabetes and Glycemia on Cardiac Improvement and Adverse Events Following Mechanical Circulatory Support. Journal of the American Heart Association. https://doi.org/10.1161/jaha.123.032936

Vancouver

Kyriakopoulos CP, Taleb I, Tseliou E, Sideris K, Hamouche R, Maneta E, et al. Impact of Diabetes and Glycemia on Cardiac Improvement and Adverse Events Following Mechanical Circulatory Support. Journal of the American Heart Association. 2024. doi:10.1161/jaha.123.032936

BibTeX
@article{Kyriakopoulos2024,
  author = {Kyriakopoulos, Christos P and Taleb, Iosif and Tseliou, Eleni and Sideris, Konstantinos and Hamouche, Rana and Maneta, Eleni and Nelson, Marisca and Krauspe, Ethan and Selko, Sean and Visker, Joseph R and Dranow, Elizabeth and Goodwin, Matthew L and Alharethi, Rami and Wever-Pinzon, Omar and Fang, James C and Stehlik, Josef and Selzman, Craig H and Hanff, Thomas C and Drakos, Stavros G},
  title = {Impact of Diabetes and Glycemia on Cardiac Improvement and Adverse Events Following Mechanical Circulatory Support},
  journal = {Journal of the American Heart Association},
  year = {2024},
  doi = {10.1161/jaha.123.032936}
}
Kostenlos starten →